Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.33 USD
Change Today -0.34 / -4.43%
Volume 779.8K
PGNX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $1.937 million compared to $1.477 million a year ago. Operating loss was $11.708 million compared to $11.087 million a year ago. Net loss before income tax benefit was $11.697 million compared to $11.074 million a year ago. Net loss was $11.697 million or $0.17 per basic and diluted share compared to $11.073 million or $0.16 per basic and diluted share a year ago. For the six months, the company reported total revenues of $2.185 million compared to $3.292 million a year ago. Operating loss was $21.974 million compared to $20.412 million year ago. Net loss before income tax benefit was $21.951 million compared to $20.387 million a year ago. Net loss was $21.951 million or $0.32 per basic and diluted share compared to $20.386 million or $0.31 per basic and diluted share a year ago.

Progenics Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Progenics Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Progenics Pharmaceuticals, Inc. Plans for 1404 Phase 3 Clinical Trial

Progenics Pharmaceuticals, Inc. announced details of its planned Phase 3 clinical trial for 1404, a developmental stage small molecule designed to help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA). Following recent End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), the design and key elements of a Phase 3 clinical trial for 1404 have been finalized. The Phase 3 clinical trial is expected to enroll approximately 450 patients with biopsy-proven low-grade prostate cancer who are candidates for active surveillance but have planned to undergo radical prostatectomy (RP). The multicenter, multi-reader, open-label study will evaluate the specificity and sensitivity of 1404 to identify clinically significant prostate cancer. Histopathology of the tumor tissue will be used as the truth standard. An interim analysis will be performed after approximately one-third of the subjects have been treated and will include an analysis for futility and also evaluate the need for a sample size re-estimation.

Robert J. Israel Steps Down as Executive Vice President, Innovation of Progenics Pharmaceuticals

Dr. Robert J. Israel stepped down as Executive Vice President, Innovation of Progenics Pharmaceuticals, Inc. to pursue other interests, effective July 2, 2015.

Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that Valeant submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. RELISTOR is a peripherally acting mu-opioid receptor antagonist specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. RELISTOR does not cross the blood-brain barrier, therefore relieving the distressing effects of the constipation without affecting the analgesic effect of the opioid. RELISTOR Subcutaneous Injection has been FDA approved since 2008 to treat OIC in patients with advanced illness who are receiving palliative care, and was approved in 2014 for the treatment of OIC in patients with chronic non-cancer pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $7.33 USD -0.34

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $14.80 USD -0.31
Arena Pharmaceuticals Inc $2.71 USD 0.00
Array BioPharma Inc $5.90 USD -0.04
CTI BioPharma Corp $1.58 USD -0.02
Inovio Pharmaceuticals Inc $7.49 USD -0.24
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 100.0x
Price/Sales 12.3x
Price/Book 5.1x
Price/Cash Flow 158.4x
TEV/Sales 10.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.